Without any doubt, immune checkpoint inhibition has revolutionized the management of patients with metastatic melanoma, dramatically improving their prognosis, and is considered the standard treatment ...

Immune checkpoint blockade (ICB) has reshaped modern immunotherapy by unleashing antitumor immune responses through targeting inhibitory immune checkpoints ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

The immune checkpoint inhibitors market presents opportunities in next-gen therapies targeting new immune checkpoints, boosting treatment efficacy, especially for difficult-to-treat cancers. Growth is ...

SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S.

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...

A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.